Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $606 Million
- Q4 2024
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 8,019,354 shares of DYN stock, worth $109 Million. This represents 31.16% of its overall portfolio holdings.
Number of Shares
8,019,354
Previous 8,020,136
0.01%
Holding current value
$109 Million
Previous $288 Million
34.42%
% of portfolio
31.16%
Previous 35.54%
Shares
5 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Black Rock Inc. New York, NY7.39MShares$101 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$100 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$91.2 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$86.8 Million2.43% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$74.3 Million21.73% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $705M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...